-
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
29 Mar 2024 05:54 GMT
… 5339 received Clinical Trial Application approval from … trials as combination agent with rituximab for the treatment … .
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is … and Drug Administration, European Medicines Agency, PRC National Medical Products …
-
Soliris reimbursement in NMOSD treatment offers hope for relapse-free lives
29 Mar 2024 02:33 GMT
… eligible for rituximab. They must have undergone treatment for a … events.
Continuation of Soliris treatment is assessed through neurologic … -blind, phase 3 clinical trial. This study confirmed the … area of significant unmet medical need for both patients …
-
Genmab files patent for treatment of diffuse large B-cell lymphoma using bispecific antibody
26 Mar 2024 15:58 GMT
… epcoritamab or a biosimilar thereof, rituximab, cyclophosphamide, doxorubicin, vincristine, and … and schedules, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and … treatment approach for DLBCL using a specific combination of drugs …
-
Granulomatosis With Polyangiitis Market Report 2032: Epidemiology, Therapies, Latest FDA, EMA, Approvals by DelveInsight
26 Mar 2024 13:26 GMT
… with cyclophosphamide or rituximab, with adjuvant therapy … studies conducted in treatment trials have improved understanding … unique opportunities for pharmaceutical companies to pioneer … With Polyangiitis Current Treatment and Medical Practices
10. …
-
Trial Reveals Long-Term Success of First-Line Rituximab Treatment for Pemphigus Patients
25 Mar 2024 19:34 GMT
… first-line treatment approach utilizing rituximab. The findings of this trial, conducted … Patients who received rituximab as a first-line treatment showcased significantly longer … impact of treatment initiation, noting that patients who received rituximab as …
-
Man sent home with depression by doctors actually had rare 'walking on hot coals' condition
25 Mar 2024 18:24 GMT
… doctors saying he had just a few days to live without treatment … pills a day, including one called Rituximab, which was part of a trial … . Thankfully, this medicine worked …
-
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
28 Mar 2024 13:00 GMT
… clinical trial to evaluate MB-106 for the treatment of … autoimmune diseases, such as rituximab for both lymphoma and … Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). … starting and completing clinical trials; uncertainties relating to preclinical …
-
Membranous Nephropathy Market Size is anticipated to Grow by 2032, estimates DelveInsight
27 Mar 2024 11:24 GMT
… Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals … clinical trials for … Drugs Profile
• Calcineurin inhibitors
• Rituximab
• Steroids
• Alkylating agents and others
Membranous Nephropathy Treatment … Treatment Algorithm, Current Treatment, and Medical …
-
Focal Segmental Glomerulosclerosis Market to to Grow Rapidly During the Forecast Period (2023-2032) | DelveInsight
26 Mar 2024 15:44 GMT
… Segmental Glomerulosclerosis Drugs Uptake and … VX-147: Vertex Pharmaceuticals
Losmapimod: GlaxoSmithKline
Propagermanium … ChemoCentryx
Dapagliflozin: AstraZeneca
rituximab: Genentech, Inc.
… Glomerulosclerosis Current Treatment and Medical Practices
10. …
-
Graft Versus Host Disease Market Size is expected to grow by 2032, according to estimates DelveInsight
26 Mar 2024 07:15 GMT
… trials for Colonoscopy. This phase I trial … belumosudil and rituximab as primary treatment of cGVHD. … 2015, the Pharmaceuticals and Medical Devices Agency (PMDA … Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceutical, Kadmon Corporation …